PROCYON BIOPHARMA INC ("PBP-V") - CEO Emphasizes: Company not Linked to Human
Genome Project
The President and CEO of Procyon BioPharma Inc.("Procyon") emphasized that the activities of
Procyon are not linked to the Human Genome Project and that shareholders need not be concerned
about the impact of the Clinton, Blair announcement in this regard.
Mr. Mader pointed out that Procyon is on target with the development of its two core technologies
and its two near-term products. "Since moving our head office to Montreal, Procyon has benefitted
from the synergies of the vibrant biotech environment in this region," he said. "We announced an
agreement by which Biovail has acquired the Canadian rights to FIBROSTAT(TM), our topical
cream in late Phase II development for the treatment of scars resulting from surgery or burns." The
agreement provides Procyon with up-front financing to complete development of the product and a
milestone payment upon product approval, in addition to double-digit royalties on sales.
Procyon BioPharma Inc. is a publicly listed, biopharmaceutical company focused principally on
advancing two powerful platform technologies that have the potential to diagnose and treat cancer.
Procyon's Antinuclear Autoantibodies (ANAs) bind specifically to multiple cancer cell types strongly
enhancing the immune response to cancer cells. Prostate Secretory Protein (PSP94) is a naturally
occurring human protein that has the potential to treat prostate cancer by inhibiting abnormal
prostate cell growth. In addition, the estimation of PSP94 levels in prostate cancer patients may
have prognostic and diagnostic applications. Procyon also has two late-stage products:
FIBROSTAT(TM), a topical cream for the management of newly formed scars following surgery or
burns and COLOPATH(TM), a rapid, non-invasive screening test for colorectal cancer.
Procyon's shares trade on the CDNX under the ticker symbol, PBP. TEL: (514) 685-9283 Hans J.
Mader, President and CEO
Procyon BioPharma Inc. E-mail: hmader@procyonbiopharma.com Web site:
www.procyonbiopharma.com TEL: (514) 843-2309 Nathalie Bourque
NATIONAL Public Relations
______________________________ |
